Literature DB >> 16218042

A case-controlled study on the quality of life in a cohort of patients with history of differentiated thyroid carcinoma.

M Giusti1, F Sibilla, C Cappi, M Dellepiane, F Tombesi, E Ceresola, C Augeri, E Rasore, F Minuto.   

Abstract

Although quality of life (QoL) has become an important aspect of cancer rehabilitation, psychometric studies on thyroid cancer patients are rare. We performed a case-controlled study on QoL in patients with differentiated thyroid carcinoma (DTC). QoL was evaluated in 61 patients with a history of DTC diagnosed from < 1 to 23 yr earlier. An undetectable thyroglobulin (Tg) level after recombinant human TSH (rhTSH) testing was considered the best predictor of cure. QoL was evaluated by means of a general psychiatric interview, the self-rating Kellner Symptoms Questionnaire (KSQ) and the Hamilton Depression Scale (HDS). QoL was also evaluated in a control group of subjects on L-T4 therapy with a non-toxic multinodular goiter diagnosed from < 1 to 25 yr earlier. DTC and control subjects were similar in age, male-female distribution and concomitant psychiatric therapies. Per-week dosage of L-T4 was higher in DTC patients than in controls (p < 0.01). In neither group of subjects was there any correlation between current TSH levels or interval from diagnosis and KSQ or HDS scores. Only in DTC patients was there a positive correlation between age and KSQ (p < 0.05) or HDS (p < 0.01) scores. There was a significant difference in overall KSQ scores between DTC (33.4 +/- 2.1) and control (24.5 +/- 1.9; p < 0.01) subjects. The subscales of KSQ showed a significant inter-group difference. HDS scores were higher in DTC subjects (35.8 +/- 1.0) than in controls (30.0 +/- 1.1; p < 0.01). HDS score was significantly (p = 0.02) higher in female than in male DTC patients. In patients with papillary carcinoma there was a positive correlation between the MACIS (metastases, age, completeness, invasiveness, size) score and KSQ (p = 0.01) or HDS (p < 0.01) scores. After rhTSH testing, detectable Tg levels were found in 13% of DTC patients. In Tg-positive patients, KSQ and HDS scores were not different from those of Tg-negative patients. After an 8-14 month period, a significant decrease in the KSQ scale somatization (p = 0.02) was found in a sub-set of 31 DTC patients. In conclusion, even in the age of rhTSH testing, DTC patients suffer an impairment of their QoL, as noted when short-term L-T4 withdrawal was the gold standard. Longitudinal evaluation seems to indicate a slight improvement in QoL when safe rhTSH testing is extensively used in the management of the disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16218042     DOI: 10.1007/bf03347258

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  29 in total

1.  Guidelines for the management of thyroid cancer.

Authors:  Pat Kendall-Taylor
Journal:  Clin Endocrinol (Oxf)       Date:  2003-04       Impact factor: 3.478

Review 2.  Papillary and follicular thyroid carcinoma.

Authors:  M J Schlumberger
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

3.  Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy.

Authors:  K H Dow; B R Ferrell; C Anello
Journal:  Thyroid       Date:  1997-08       Impact factor: 6.568

Review 4.  Thyroid carcinoma.

Authors:  Steven I Sherman
Journal:  Lancet       Date:  2003-02-08       Impact factor: 79.321

5.  Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991.

Authors:  F D Gilliland; W C Hunt; D M Morris; C R Key
Journal:  Cancer       Date:  1997-02-01       Impact factor: 6.860

6.  Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases.

Authors:  Massimo Torlontano; Marco Attard; Umberto Crocetti; Salvatore Tumino; Rocco Bruno; Giuseppe Costante; Girolamo D'Azzò; Domenico Meringolo; Elisabetta Ferretti; Rosario Sacco; Franco Arturi; Sebastiano Filetti
Journal:  J Clin Endocrinol Metab       Date:  2004-07       Impact factor: 5.958

7.  Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma.

Authors:  F Pacini; E Molinaro; M G Castagna; L Agate; R Elisei; C Ceccarelli; F Lippi; D Taddei; L Grasso; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  2003-08       Impact factor: 5.958

8.  Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxine supplementation therapy.

Authors:  Richard Crevenna; Georg Zettinig; Mohammad Keilani; Martin Posch; Manuela Schmidinger; Christian Pirich; Martin Nuhr; Michael Wolzt; Michael Quittan; Veronika Fialka-Moser; Robert Dudczak
Journal:  Support Care Cancer       Date:  2003-06-03       Impact factor: 3.603

Review 9.  Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective.

Authors:  Martin Schlumberger; Gertrud Berg; Ohad Cohen; Leonidas Duntas; François Jamar; Barbara Jarzab; Eduard Limbert; Peter Lind; Furio Pacini; Christoph Reiners; Franco Sánchez Franco; Anthony Toft; Wilmar M Wiersinga
Journal:  Eur J Endocrinol       Date:  2004-02       Impact factor: 6.664

10.  Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.

Authors:  M Giusti; R Zoccola; B Guazzini; E Molinari; S Valenti; G Villa; L Bertolazzi; F Minuto
Journal:  Minerva Endocrinol       Date:  2003-09       Impact factor: 2.184

View more
  14 in total

1.  Quality of life is not influenced by the extent of surgery in patients with benign goiter.

Authors:  F Hubertus Schmitz-Winnenthal; Simon Schimmack; Ben Lawrence; Uwe Maier; Miriam Heidmann; Markus W Buchler; Moritz von Frankenberg
Journal:  Langenbecks Arch Surg       Date:  2011-08-02       Impact factor: 3.445

2.  Five-year longitudinal evaluation of quality of life in a cohort of patients with differentiated thyroid carcinoma.

Authors:  Massimo Giusti; Giulia Melle; Monica Fenocchio; Lorenzo Mortara; Francesca Cecoli; Valeria Caorsi; Diego Ferone; Francesco Minuto; Elda Rasore
Journal:  J Zhejiang Univ Sci B       Date:  2011-03       Impact factor: 3.066

Review 3.  Prognostic utility of BRAF mutation in papillary thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Mol Cell Endocrinol       Date:  2009-10-31       Impact factor: 4.102

4.  The impact of thyroidectomy on psychiatric symptoms and quality of life.

Authors:  P Miccoli; M N Minuto; R Paggini; P Rucci; A Oppo; G Donatini; F Golia; L Novelli; M Carlini; L Dell'Osso
Journal:  J Endocrinol Invest       Date:  2007-11       Impact factor: 4.256

5.  Health-Related Quality of Life and Cosmesis After Thyroidectomy: Long-Term Outcomes.

Authors:  Dimitrios Linos; Spyridon Christodoulou; Vassiliki Kitsou; Angeliki Karachaliou; Spyridon Ntelis; Athanassios Petralias
Journal:  World J Surg       Date:  2020-01       Impact factor: 3.352

6.  Decreased health-related quality of life in disease-free survivors of differentiated thyroid cancer in Korea.

Authors:  Ji In Lee; Soo Hyun Kim; Alice H Tan; Hee Kyung Kim; Hye Won Jang; Kyu Yeon Hur; Jae Hyeon Kim; Kwang-Won Kim; Jae Hoon Chung; Sun Wook Kim
Journal:  Health Qual Life Outcomes       Date:  2010-09-15       Impact factor: 3.186

7.  Recombinant human thyroid stimulating hormone in 2008: focus on thyroid cancer management.

Authors:  Ann Gramza; Kathryn G Schuff
Journal:  Onco Targets Ther       Date:  2009-01-01       Impact factor: 4.147

8.  'I know I'm not invincible': An interpretative phenomenological analysis of thyroid cancer in young people.

Authors:  Stephanie Smith; Virginia Eatough; James Smith; Radu Mihai; Andrew Weaver; Gregory P Sadler
Journal:  Br J Health Psychol       Date:  2018-01-22

9.  The impact of thyroid cancer and post-surgical radioactive iodine treatment on the lives of thyroid cancer survivors: a qualitative study.

Authors:  Anna M Sawka; David P Goldstein; James D Brierley; Richard W Tsang; Lorne Rotstein; Shereen Ezzat; Sharon Straus; Susan R George; Susan Abbey; Gary Rodin; Mary Ann O'Brien; Amiram Gafni; Lehana Thabane; Jeannette Goguen; Asima Naeem; Lilian Magalhaes
Journal:  PLoS One       Date:  2009-01-14       Impact factor: 3.240

10.  Evaluation of Quality of Life in Patients with Differentiated Thyroid Cancer by Means of the Thyroid-Specific Patient-Reported Outcome Questionnaire: A 5-Year Longitudinal Study.

Authors:  Massimo Giusti; Stefano Gay; Lucia Conte; Francesca Cecoli; Lorenzo Mortara; Lara Vera; Eleonora Monti
Journal:  Eur Thyroid J       Date:  2019-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.